This company is releasing data for phase one clinical trial data for a cancer treatment drug. The risk is high, but if the data is good, The stock could rise 200+%.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
